{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Zepzelca",
    "query": {
      "intervention": "Zepzelca"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T03:19:28.614Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04894591",
      "title": "To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Zepzelca",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2021-06-28",
      "completion_date": "2025-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Norwich, Connecticut • Brooksville, Florida + 29 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04894591"
    },
    {
      "nct_id": "NCT05099666",
      "title": "Lurbinectedin + Doxorubicin In Leiomyosarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Soft-tissue Sarcoma",
        "Metastatic Soft-tissue Sarcoma",
        "Advanced Leiomyosarcoma",
        "Leiomyosarcoma Metastatic"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2022-02-04",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099666"
    },
    {
      "nct_id": "NCT04607954",
      "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-Resistant Lung Small Cell Carcinoma",
        "Platinum-Sensitive Lung Small Cell Carcinoma",
        "Recurrent Extensive Stage Lung Small Cell Carcinoma",
        "Refractory Extensive Stage Lung Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2020-12-04",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04607954"
    },
    {
      "nct_id": "NCT05244239",
      "title": "Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extensive Stage Lung Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Palliative Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-07-27",
      "completion_date": "2027-07-28",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05244239"
    },
    {
      "nct_id": "NCT07459634",
      "title": "A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-30",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07459634"
    },
    {
      "nct_id": "NCT05042934",
      "title": "Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Ewing Sarcoma",
        "Recurrent Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Fine-Needle Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-09-15",
      "completion_date": "2022-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05042934"
    },
    {
      "nct_id": "NCT05229588",
      "title": "Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Malignancies"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin 4 MG Injection [Zepzelca]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-06-14",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05229588"
    },
    {
      "nct_id": "NCT06681220",
      "title": "Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Small Cell Lung Cancer",
        "Recurrent Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stenoparib/Temozolomide",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2026-02-23",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-04T03:19:28.614Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06681220"
    }
  ]
}